540 related articles for article (PubMed ID: 18422482)
21. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide.
Miehlke S; Madisch A; Voss C; Morgner A; Heymer P; Kuhlisch E; Bethke B; Stolte M
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1115-9. PubMed ID: 16305725
[TBL] [Abstract][Full Text] [Related]
22. [Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH].
Dejaco C; Haas T; Kirchgatterer A; Miehsler W; Wenzl H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W; Tilg H
Z Gastroenterol; 2006 Jun; 44(6):525-38; discussion 539. PubMed ID: 16773519
[TBL] [Abstract][Full Text] [Related]
23. [Locally acting corticosteroids in inflammatory bowel disease. Are they effective? Are they really less toxic?].
Nos Mateu P
Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():16-21. PubMed ID: 19087859
[No Abstract] [Full Text] [Related]
24. Time to remission with budesonide in collagenous colitis.
Miehlke S; Madisch A; Bethke B; Stolte M
Aliment Pharmacol Ther; 2005 Jun; 21(12):1507-8; author reply 1508. PubMed ID: 15948819
[No Abstract] [Full Text] [Related]
25. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial.
Bonderup OK; Hansen JB; Teglbjaerg PS; Christensen LA; Fallingborg JF
Gut; 2009 Jan; 58(1):68-72. PubMed ID: 18669576
[TBL] [Abstract][Full Text] [Related]
26. [Budesonide and inflammatory bowel disease].
Gomollón F; Hinojosa J; Nos P
Gastroenterol Hepatol; 1999 Dec; 22(10):525-32. PubMed ID: 10650668
[No Abstract] [Full Text] [Related]
27. Lymphocytic colitis in a patient with psoriasis responsive to budesonide.
Wiedermann CJ; Zelger A
Scand J Gastroenterol; 2007 Apr; 42(4):538-9. PubMed ID: 17454870
[No Abstract] [Full Text] [Related]
28. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
McKeage K; Goa KL
Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
[TBL] [Abstract][Full Text] [Related]
29. Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy.
Hamedani R; Feldman RD; Feagan BG
Aliment Pharmacol Ther; 1997 Dec; 11 Suppl 3():98-107; discussion 107-8. PubMed ID: 9467984
[TBL] [Abstract][Full Text] [Related]
30. Oral budesonide in the treatment of chronic refractory pouchitis.
Gionchetti P; Rizzello F; Poggioli G; Pierangeli F; Laureti S; Morselli C; Tambasco R; Calabrese C; Campieri M
Aliment Pharmacol Ther; 2007 May; 25(10):1231-6. PubMed ID: 17451569
[TBL] [Abstract][Full Text] [Related]
31. Microscopic colitis: an update.
Tangri V; Chande N
J Clin Gastroenterol; 2009 Apr; 43(4):293-6. PubMed ID: 19169149
[TBL] [Abstract][Full Text] [Related]
32. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
[TBL] [Abstract][Full Text] [Related]
33. The role of Budesonide-MMX in active ulcerative colitis.
Gionchetti P; Praticò C; Rizzello F; Calafiore A; Capozzi N; Campieri M; Calabrese C
Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):215-22. PubMed ID: 24502535
[TBL] [Abstract][Full Text] [Related]
34. Treatment of inflammatory bowel disease with corticosteroids.
Katz JA
Gastroenterol Clin North Am; 2004 Jun; 33(2):171-89, vii. PubMed ID: 15177533
[TBL] [Abstract][Full Text] [Related]
35. Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease.
Pietra M; Fracassi F; Diana A; Gazzotti T; Bettini G; Peli A; Morini M; Pagliuca G; Roncada P
Am J Vet Res; 2013 Jan; 74(1):78-83. PubMed ID: 23270349
[TBL] [Abstract][Full Text] [Related]
36. [Budesonide: effective, with low side effects. On the road to new treatment methods in Crohn disease].
Internist (Berl); 1998 Sep; 39(9 Suppl Auf Dem We):1-8. PubMed ID: 9772715
[No Abstract] [Full Text] [Related]
37. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
Abreu MT
Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):210-1. PubMed ID: 16265201
[No Abstract] [Full Text] [Related]
38. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis.
Bajor A; Kilander A; Gälman C; Rudling M; Ung KA
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1643-9. PubMed ID: 17094773
[TBL] [Abstract][Full Text] [Related]
39. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
40. Budesonide multi-matrix system formulation for treating ulcerative colitis.
Prantera C; Scribano ML
Expert Opin Pharmacother; 2014 Apr; 15(6):741-3. PubMed ID: 24484392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
